Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib

David Marín, Alexandra Bazeos, François-Xavier Mahon, +17

Journal of Clinical Oncology

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure

Timothy P. Hughes, Michael J. Mauro, Jörge E. Cortes, +27

New England Journal of Medicine

BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia

Matthew S. Zabriskie, Christopher A. Eide, Srinivas K. Tantravahi, +39

Cancer Cell

Hematological MalignancyPh Chromosome-positive LeukemiaGeneticsMolecular GeneticsCancer Genetics +5

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

Philipp le Coutre, Oliver G. Ottmann, Francis J. Giles, +20

Blood

Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase

François-Xavier Mahon, Carla Boquimpani, Dong‐Wook Kim, +17

Annals of Internal Medicine

Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib

Timothy P. Hughes, Jeffrey H. Lipton, Nelson Spector, +12

Blood

Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec®) in vitro and in vivo

Jérôme Larghero, Thibaut Leguay, Samia Mourah, +11

Biochemical Pharmacology

Hematological MalignancyAcid GlycoproteinMedicineImmunologyAlpha 1 +5

Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study

Francis J. Giles, Gianantonio Rosti, Photis Beris, +6

Expert Review of Hematology

Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update

Timothy P. Hughes, Nelma Cristina D. Clementino, Mikhail Fominykh, +11

Leukemia

Hematological MalignancyChronic Myeloid LeukemiaOncologyMixed-phenotype Acute LeukemiaHematology +8

Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness

Alexandre Puissant, Maeva Dufies, Nina Fenouille, +14

Journal of Molecular Cell Biology